Good morning, 360!
Don’t forget to join us today for LIVE trading in the Market Master’s Room — and for OPTIONS BOOTCAMP with JW starting TONIGHT at 7pm EST. Be the best prepared trader on the Street!
FOCUS LIST🔎
DJT – Up over 50% in the pre-market after defiant Trump survives and shrugs off assassination attempt
SCNI – Up over 50% in pre after announces promising results in an in-vivo proof-of-concept psoriatic human skin model
MIRA – Up over 60% in pre after preclinical study shows MIRA-55’s enhanced efficacy over THC in treating anxiety and cognitive decline
New to options & not sure where to start?
Mark Your Calendars & Invite a Friend!
This is for YOU Mon – Wed
HOTLIST🔥
DJT – Up over 50% in the pre-market after defiant Trump survives and shrugs off assassination attempt
Trump Media & Technology Group Corp. (DJT) develops a social media platform known as Truth Social that offers social networking services in the United States. It is a Donald Trump majority owned Social Media company.
Over the weekend Donald Trump survived an assassination attempt by a lone gunman at a rally in Pennsylvania. Iconic images showed Trump bleeding from the ear, with a bullet missing his brain by inches, willing on supporters to ‘fight, fight, fight’. His popularity has surged with influencers such as Elong Musk and Bill Ackman endorsing the former president as their choice in the coming election.
DJT stock is up over 50% in reaction to the weekend’s events.
The $45 area has acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $47.25, $50, $52.75 and then the pre-market high at $54.49. Beyond that, $56.50, $58.72, and $70 come into play.
Below $45, targets to the downside are $42, $40, $32.10 and then a gap fill at $30.89.
SCNI – Up over 50% in pre after announces promising results in an in-vivo proof-of-concept psoriatic human skin model
Scinai Immunotherapeutics Ltd. (SCNI) is a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel.
In the pre-market this morning, the company announced successful in-vivo preclinical study results of its innovative anti IL-17A/F VHH antibody fragment (‘NanoAb’) as a local, first of its kind, intralesional biological treatment for the large and underserved population of patients suffering from mild to moderate plaque psoriasis.
Scinai’s product candidate is designed to address the major shortcomings of currently available treatments. It is a biologic, intended to be delivered locally, intradermally, into the psoriatic lesions using a very short and almost painless needle. Scinai’s product is designed to allow patients with mild to moderate psoriasis to benefit from a low frequency treatment that comes with the high specificity and potency saved for biologics but with significantly reduced risk of local side effects associated with corticosteroids or systemic side effects associated with systemic administration of biologics.
Dr. Tamar Ben-Yedidia, Scinai’s Chief Scientist, noted, “These positive results are very encouraging and mark a significant step forward in the development of a novel treatment for the underserved needs of the mild to moderate plaque psoriatic patients.
The stock traded up over 50% in the pre-market in reaction to the news.
The $5.70 area has acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $6, $6.50, $6.70, $7.50, $8 and then the pre-market high at $8.36. Beyond that $9 and $10 come into play.
Below $5.70, targets to the downside are $5, $4.50 and $4.06.
MIRA – Up over 60% in pre after preclinical study shows MIRA-55’s enhanced efficacy over THC in treating anxiety and cognitive decline
MIRA Pharmaceuticals Inc. (MIRA) operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.
One is an oral Ketamine treatment. The other is its oral pharmaceutical marijuana, MIRA-55 that is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
In the pre-market this morning, the company announced its preclinical study shows MIRA-55’s enhanced efficacy over THC in treating anxiety and cognitive decline.
Key findings include:
Higher efficacy at CB1 and CB2 cannabinoid receptors compared to THC
More pronounced and sustained agonist activity as concentration increases
Consistent, dose-dependent reduction in anxiety-like behaviors
Maintained efficacy across a broader range of doses
Promising toxicological profile, indicating potential safer profile for human use
The stock traded up over 60% in the pre-market in reaction to the news.
The first target for bulls is the pre-market high at $1.25.
Beyond that $1.45, $1.70 and $1.84 come into play.
Below $1.25, targets to the downside are $1.10, $1, $0.90, $0.80, $0.70 and then a gap fill at $0.5892.
MARKET NEWS 📰
*sponsored by the Rundown
Keep up with AI
How do you keep up with the insane pace of AI? Join The Rundown — the world’s largest AI newsletter that keeps you up-to-date with everything happening in AI with just a 5-minute read per day.
👊 Make sure you are getting my mobile text alerts – text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out!
Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (“RagingBull”) subscription, website, application or other service (“Services”), please review our full disclaimer located at https://ragingbull.com/disclaimer.
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers’ trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers mentioned in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
*Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals.
RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled.
